Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the results from a completed phase II study with the investigational FLT3 inhibitor, quizartinib , as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia .1,2 < 60 years with AML relapsed in <1 year or refractory to 1st-line ... (more)
http://www.businesswire.com/news/topix/20121211005807/en
http://www.businesswire.com/news/topix/20121211005807/en
No comments:
Post a Comment